Login to Your Account

Acea's third-gen EGFR races Tagrisso to China approval in lung cancer

By Shannon Ellis
Staff Writer

Friday, December 16, 2016

SHANGHAI – Acea Biosciences Inc. presented efficacy, safety and tolerability data from its China phase I/II dose-escalation and expansion study of AC0010, a third-generation EGFR tyrosine kinase inhibitor at the World Conference on Lung Cancer (WCLC) 2016 in Vienna.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription